- Novartis’ Kisqali receives positive CHMP opinion for reducing recurrence risk in HR+/HER2- early breast cancer, potentially doubling eligible patients for adjuvant treatment in Europe.
- Based on Phase III NATALEE trial, Kisqali with endocrine therapy reduced recurrence risk by 25%. The decision follows FDA approval and supports Kisqali’s use in a broad patient population, including high-risk node-negative cases.
- Final EC decision expected in two months.
Fri Oct 18 11:52:03 -2024 UTC– Novartis receives positive CHMP opinion for Kisqali® for adjuvant treatment of HR+/HER2- early breast cancer.
Kisqali reduces recurrence risk by 25% in Phase III NATALEE trial, targeting a broad patient population. Approval may expand adjuvant therapy options in Europe.
Breast cancer is a common diagnosis, with Kisqali showing promise in reducing recurrence rates. Kisqali’s potential benefits are emphasized, awaiting final EC decision within two months.
Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:
About Lisa
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter
Read more Business News as it happens!
Business